However, the future of immune checkpoint therapy in liver cancer still remains unclear, with the failure of phase III clinical trial [52] (anti-PD-1) despite a small proportion (15%) of response to PD-1 inhibitor in phase II clinical trial [53]. This evidence concerns the gene PDCD1 and liver cancer.